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ABSTRACT
Associations between growth factor receptor-mediated cell signaling and 
cancer cell growth have been previously characterized. Receptors for prostaglandin 
E2, such as EP2, and EP4, play roles in cancer growth, progression and invasion. 
Thus, we examined the interactions between EP2/EP4- and IGF-1R-mediated 
cellular signaling in human pancreatic cancer cells. Selective antagonists against 
EP2 and EP4 abrogated IGF-1-stimulated cell growth and suppressed MEK/ERK 
phosphorylation. In subsequent experiments, phospho-antibody arrays indicated 
increased phosphorylation levels of protein kinase C-θ (PKC-θ) at the Thr538 position 
following the inhibition of EP2/EP4-mediated signaling. Inhibition of PKC-θ activity 
impaired cell viability compared with EP2/EP4-antagonized IGF-1-stimulated cells. 
PKC-θ kinase MAP4K3, which plays a pivotal role in PKC-θ activation, also affected 
growth signaling in the presence of EP2/EP4 antagonists. Administration of EP2 and 
EP4 antagonists significantly inhibited the growth of an orthotopic xenograft of IGF-
1-secreting pancreatic cancer cells, with increased phospho-PKC-θ and decreased 
phospho-ERK. Clinico-pathological analyses showed that 17.4% of surgical pancreatic 
cancer specimens were quadruple-positive for IGF-1R, EP2 (or EP4), MAP4K3, and 
PKC-θ. These results indicate a novel signaling crosstalk between EP2/EP4 and IGF-
1R in cancer cells, and suggest that the MAP4K3-PKC-θ axis is central and could be 
exploited as a molecular target for cancer therapy.
INTRODUCTION
Growth factor receptor-mediated signaling is 
known to be important for cancer cell growth, tumor 
development, metastasis and various other events in 
several types of cancer, including pancreatic carcinomas 
[1-5]. Therefore, most therapeutic molecular targets 
involve the kinase activities of growth factor receptors 
and their ligands [6]. Insulin-like growth factor-1 and 
-2 (IGF-1 and -2, respectively) and their receptors (IGF-
1R) are potential targets that trigger multiple intracellular 
signaling pathways [5, 7]. The circulating IGF-1 levels are 
closely associated with the risk of cancer [8, 9], and the 
blockade of IGF-1R, using anti-IGF-R1 antibodies, IGF1R 
antisense, and inhibitory analogues of IGF-1 suppress 
tumor cell growth and angiogenesis [10-13]. In patients 
with several cancers including pancreatic cancer, high 
expression of IGF-1R in tumors is associated with higher 
tumor grades and poor survival [14, 15]. In vitro studies 
have shown that exogenous IGF-1-stimulated growth 
of pancreatic cancer cell lines is abrogated following 
treatment with anti-IGF1R antibodies [16]. 
Prostaglandins such as prostaglandin E2 (PGE2), 
are also associated with cancer cell growth, tumor 
development and metastasis, as well as with inflammation 
and other physiological events [17,18]. Cycooxygenase-2 
(COX-2) is an inducible enzyme that converts arachidonic 
acid into prostaglandins, and its roles in the development 
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of many tumor types have been demonstrated in genetic 
and inhibitor studies, histopathological analyses, and 
epidemiological studies [19-23]. PGE2 receptors or 
E-prostanoid receptors (EPs) comprise several subtypes 
(EP1-EP4), which can be classified into three types based 
on their signaling features [24]. Both basic and clinical 
studies have reported increased PGE2 production and 
the overexpression of EPs in tumor tissues in pancreatic 
cancer, as well as in a wide range of cancers [25, 26]. 
Therefore, EP-mediated cellular signaling may be a potent 
antitumor target, which could be exploited using specific 
antagonists of EPs or COX.
Numerous interactions between growth factor 
receptor-mediated signaling pathways have been shown 
to play pivotal roles in accelerated cancer cell growth, 
invasion, and metastasis. In particular, the interactions 
between IGF-1R, epidermal growth factor receptor 
(EGFR), platelet-derived growth factor receptor, and 
estrogen receptors have been reported to synergistically 
potentiate cell proliferation [27-29]. Moreover, the 
transactivation of EP and EGFR, and the subsequent 
activation of mitogenic signaling have also been 
demonstrated in several cancers [30-32]. However, 
reciprocal combinations between EPs and other growth 
factor receptors, including IGF-1R, have not been fully 
elucidated. In the present study, we checked for the 
presence of alternative signaling interactions between 
EPs and IGF-1R mainly in pancreatic cancer cells using 
selective antagonists against EP2 and EP4. Thereafter, 
phospho-antibody arrays were used to determine the 
molecular relationships between EPs and IGF-1R 
signaling, where in vivo experiments and clinico-
pathological analyses were performed to demonstrate the 
molecular basis and probability of this signaling crosstalk.
RESULTS
Characteristics of human pancreatic cancer cells
Initially, the expression of 12 parameters was 
examined in the pancreatic cancer cell lines MiaPaCa-2, 
BxPC-3, PANC-1, and Capan-1 by RT-PCR, and the 
secretions of PGE2 in culture media (CM) were determined 
using EIA. COX-1 and COX-2 mRNA expression was 
observed in BxPC-3 cells.
Capan-1 cells expressed COX-2 mRNA, whereas 
MiaPaCa-2 and PANC-1 cells did not. Therefore, EIA 
analyses revealed the highest PGE2 levels in BxPC-3 CM 
(over 10 times than that in the other cell lines, Fig 1B). 
MiaPaCa-2 cells expressed EP4 mRNA at very low levels, 
whereas BxPC-3 cells exhibited low expression of EP2 
mRNA and high expression of EP4 mRNA. Only high EP4 
mRNA expression was observed in PANC-1 cells, whereas 
moderate EP2 mRNA expression and weak EP4 mRNA 
expression were observed in Capan-1 cells (Fig 1A). In 
subsequent experiments, similar levels of IGF-1R mRNA 
and protein, IGF-2R, and NRDc mRNA were expressed in 
all cell lines. However, IR mRNA expression was detected 
only in MiaPaCa-2 and PANC-1 cells, whereas EGFR and 
ErbB4 mRNAs were not expressed in any of the four cell 
lines (Fig 1A). 
Antagonism of EP2/EP4 signaling blocks IGF-1-
induced growth stimulation in BxPC-3 cells
To investigate the effects of the antagonism of EP2/
EP4-mediated cellular signaling on growth factor receptor-
mediated growth stimulation, we treated cells with 
EP2/EP4 antagonists, i.e., AH6809/GW627368X, and 
assessed HB-EGF-, IGF-1-, and IGF-2-mediated growth 
stimulation. Single treatments with AH6809/GW627368 
did not significantly affect cell viability in any of the cell 
lines (Fig 1C). Growth factor treatments increased the cell 
viability in all lines, but the degree of stimulation was 
relatively low in Capan-1. In BxPC-3 cells, pretreatment 
with AH6809/GW627368X completely blocked the 
growth stimulated by HB-EGF and IGF-1 and partially 
inhibited stimulation following treatment with IGF-2. In 
PANC-1 cells, pretreatment with AH6809/GW627368X 
only blocked HB-EGF-mediated growth stimulation, 
whereas growth stimulation by these growth factors was 
not affected by pretreatment with AH6809/GW627368X 
in MiaPaCa-2 and Capan-1 cells (Fig 2A). We also 
tested single treatments of AH6809 or GW627368X 
and assessed IGF-1-mediated growth stimulation in 
BxPC-3 cells. Pretreatment with GW627368X almost 
completely blocked growth stimulation by IGF-1 and 
pretreatment with AH6809 also suppressed it to a low 
but significant extent (Supplementary Fig 2A). Based on 
these results, we decided that it was appropriate to use 
AH6809/GW627368X in combination to achieve absolute 
inhibition of EP2/EP4-mediated cellular signaling. The 
same experiment was conducted using human breast 
cancer cell lines MCF-7 and MDA-MB-231, and human 
prostate cancer cell lines PC-3, DU145, and LNCaP. 
Similar inhibitory effects were also found in MCF-7 and 
DU145 cells, as well as in BxPC-3 cells (Supplementary 
Fig 2B).
In BxPC-3 cells, treatment with growth factors 
induced the phosphorylation of MEK and ERK, whereas 
pretreatment with AH6809/GW627368X attenuated their 
phosphorylation in IGF-1-treated cells (Fig 2B). Single 
treatments with AH6809/GW627368 did not affect the 
phosphorylation of MEK and ERK (Supplementary Fig 
1). No changes were observed in HB-EGF-treated cells 
and phosphorylation decreased only marginally in IGF-
2-treated cells (Fig 2B). EP4 knockdown also abrogated 
IGF-1-induced cell growth and the phosphorylation of 
MEK and ERK with similar efficacy to that following 
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pretreatment with AH6809/GW627368X (Supplementary 
Fig 3A).
Phosphorylation of protein kinase C-θ (PKC-θ) is 
induced by antagonism of EP2/EP4 signaling and 
it plays a role in cell growth and survival
Phospho-antibody arrays were used to assess 
changes in the protein phosphorylation status to identify 
molecules that are affected by antagonism of EP2/EP4 
signaling in IGF-1-treated BxPC-3 cells. Compared 
with IGF-1-treated cells, three induced proteins and 
five inhibited proteins were identified in AH6809/
GW627368X-pretreated IGF-1-treated cells with cut-off 
and fold changes of >2.0 and <0.5, respectively (Table 
1). The protein that changed the most was PKC-θ, which 
exhibited an 8.628-fold increase in the phosphorylation of 
Thr538. Consistent with this observation, immunoblotting 
detected increased phospho-PKC-θ at Thr538 in AH6809/
GW627368X-pretreated IGF-1-treated cells compared 
with IGF-1-treated cells and untreated cells (Fig 3A). 
Figure 1: Expression patterns and responses to EP2/EP4 antagonists AH6809/GW627368X in pancreatic cancer cell 
lines. A, The levels of COX-1, COX-2, EP1-EP4, IR, IGF-1R, IGF-2R, EGFR, ErbB4, NRDc, and β-actin mRNA and IGF-1R protein 
were measured in MiaPaCa-2, BxPC-3, PANC-1, and Capan-1 human pancreatic cancer cell lines. B, CM (serum-free for 48 h) from these 
cell lines were also subjected to PGE2 enzyme immunoassays. Columns, mean values (n = 4) based on two independent experiments; bars, 
SD. C, Pancreatic cancer cell lines were treated with 0.5 and 5 µM AH6809/GW627368X for 48 h and the cell viabilities were measured 
using the MTT assay. The A550 values for untreated cells were assigned as 100% and the relative percentages for treated cells are shown. 
Columns, mean percentages (n = 6); bars, SD. 
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Moreover, treatments with AH6809/GW627368X 
alone induced the phosphorylation of PKC-θ in a time-
dependent manner (Fig 3B). EP4 knockdown increased 
the phosphorylation of PKC-θ with similar efficacy 
to that following AH6809/GW627368X pretreatment 
(Supplementary Fig 2A). Because the phosphorylation 
of PKC-θ at Thr538 is associated directly with kinase 
activity [33], we examined the effect of PKC-θ inhibition 
using a pseudo-substrate as a specific inhibitor on growth 
stimulation following the antagonism of EP2/EP4 
signaling. Inhibition of the basal activity of PKC-θ by 
a pseudo-substrate suppressed IGF-1-mediated growth 
stimulation (data not shown). Together with the AH6809/
GW627368X pretreatments in the presence of the pseudo-
substrate, the number of IGF-1-treated viable cells 
further decreased by approximately 43% and the MEK 
and ERK phosphorylation levels also reduced (Fig 3C). 
However, according to both growth stimulation assays and 
immunoblotting, the knockdown of PKC-θ using a specific 
siRNA impaired the effect of AH6809/GW627368X 
pretreatment (Fig 4A). Finally, RT-PCR demonstrated 
the compensatory expression of PKC-α mRNA in PKC-α 
siRNA-transfected cells (Fig 4B).
MAP4K3 is involved in PKC-θ phosphorylation 
and the subsequent impairment of IGF-1-induced 
growth stimulation following the antagonism of 
EP2/EP4 signaling
Further analyses of phospho-PDK1 and phospho-
AMPKα were performed because the phosphorylation 
of PKC-θ is reportedly achieved by PDK1, AMPK, and 
MAP4K3 [34]. The phospho-PDK1 levels were not 
altered in IGF-1-treated cells or in AH6809/GW627368X-
pretreated IGF-1-treated cells (Fig 5A). However, AMPKα 
phosphorylation was not induced by any of the treatments 
described above and the total protein levels of PDK1, 
AMPKα, and MAP4K3 were similar in the non-treated 
cells, IGF-1-treated cells, and AH6809/GW627368X-
pretreated IGF-1-treated cells. Because commercial 
antibodies against phospho-MAP4K3 are currently 
unavailable, the MAP4K3 and PDK1 protein levels were 
knocked down using specific siRNAs (Fig 5B). MAP4K3 
knockdown abrogated the suppressive effect of AH6809/
GW627368X on IGF-1-stimulated cell growth compared 
with negative control siRNA- and PDK1 siRNA-
transfected cells (Fig 5C). To support this observation, 
immunoblotting showed that MAP4K3 knockdown 
cells failed to phosphorylate PKC-θ or to suppress the 
phosphorylation of MEK and ERK following AH6809/
GW627368X pretreatment and IGF-1 treatment (Fig 5D). 
Similar to that in AH6809/GW627368X-pretreated cells, 
the MAP4K3 knockdown abolished the suppression of 
IGF-1-stimulated cell growth, PKC-θ phosphorylation, 
and the inhibition of MEK and ERK phosphorylation in 
cells transfected with EP4 siRNA (Supplementary Fig 
3B). In the cells transfected with negative control siRNA 
or PDK1 siRNA, pretreatment with AH6809/GW627368X 
increased the phosphorylation of PKC-θ and suppressed 
the phosphorylation of MEK and ERK (Fig 5D). In 
subsequent experiments, the specific PDK1 inhibitor 
BX912 had no effects on the AH6809/GW627368X-
induced suppression of IGF-1-stimulated cell growth 
and PKC-θ, or MEK, and ERK phosphorylation 
(Supplementary Fig 4).
Administration of AH6809/GW627368X 
suppresses IGF-1-secreting pancreatic tumor 
growth in an orthotopic nude mouse xenograft 
model
We tested the effects of AH6809/GW627368X in 
an orthotopic nude mouse xenograft model to determine 
whether the aforementioned cellular events occured in 
vivo as well. The BxPC-3 cells did not express or secrete 
IGF-1 (data not shown), so we initially established stable 
transfectants expressing hmIGF-1 (BxPC-hmIGF-1). 
BxPC-hmIGF1 cells secreted hmIGF-1 into CM in 
an FBS-dependent manner. The growth rates of the 
BxPC-hmIGF1 transfectants were higher than those of 
Table 1: Results of phospho-antibody array (IGF-1R-relating molecules) in BxPC-3 treated with IGF-1 
vs. with AH/GW+ IGF-1 












Figure 2: Effect of AH6809/GW627368X on HB-EGF-, IGF-1-, and IGF-2-stimulated growth stimulation in pancreatic 
cancer cell lines. A, Cells were stimulated with HB-EGF (50 ng/mL), IGF-1 (20 ng/mL), or IGF-2 (50 ng/mL) for 48 h in the absence or 
presence of AH6809/GW627368X (5 µM each) pretreatment for 3 h and cell growth was measured using the MTT assay. The A550 values 
for untreated cells were assigned as 100% and the relative percentages for the treated cells are shown. Columns, mean percentages (n = 6); 
bars, SD. B, BxPC-3 cells were stimulated with HB-EGF (50 ng/mL), IGF-1 (20 ng/mL) and IGF-2 (50 ng/mL) for 20 min in the absence or 
presence of AH6809/GW627368X (5 µM each) pretreatment for 3 h. The levels of phosphorylated MEK, total MEK, phosphorylated ERK, 
and total ERK were determined by immunoblotting. The relative levels of phospho-MEK and -ERK were calculated using ImageJ software.
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the vector-control transfected cells (BxPC-mock), and 
treatments with AH6809/GW627368X decreased cell 
proliferation only in BxPC-hmIGF1 (Supplementary Fig 
5A-C). Intrapancreatic injection of these cells caused 
tumor formation in both groups, with larger tumors 
in BxPC-hmIGF1-injected mice. The average tumor 
weights and serum IGF-1 levels in BxPC-hmIGF1-
injected mice were significantly higher than those in 
BxPC-mock-injected mice (Supplementary Fig 5D). 
H&E staining and immunohistochemical staining 
for IGF-1 showed that these tumors were somewhat 
differentiated, and that IGF-1 expression was sustained 
during the experimental period. In addition, the number 
of Ki-67-positive cells (a marker for proliferative cells) 
significantly increased with the tumor weights in BxPC-
hmIGF1-injected mice (Supplementary Fig 5E). Thus, 
the effects of AH6809/GW627368X on pancreatic tumor 
growth were examined in BxPC-hmIGF1-bearing mice. 
The mean body weights of AH6809/GW627368X-
treated mice did not significantly change compared 
with control mice during the experimental period (Fig 
6A). The incidence of the visible tumors did not change 
(80% in control mice and 70% in AH6809/GW627368X-
treated mice); however, the tumor weights significantly 
decreased in AH6809/GW627368X-treated mice (Fig 
6A). H&E and immunohistochemical staining for IGF-
1 showed that treatment with AH6809/GW627368X did 
not alter the tumor types or IGF-1 expression (Fig 6B). 
Moreover, immunohistochemical staining for Ki-67 and 
the quantification of labeling indices indicated that the 
percentages of Ki-67-positive cells were significantly 
lower in AH6809/GW627368X-treated mice (Fig 6B). 
Next, the phosphorylation levels of PKC-θ, MEK, and 
ERK were examined by immunoblotting in tumor lesions. 
Figure 3: Involvement of PKC-θ phosphorylation in the antagonism of EP2/EP4 signaling. A, BxPC-3 cells were 
stimulated with IGF-1 (20 ng/mL) for 20 min in the absence or presence of AH6809/GW627368X (5 µM each) pretreatment for 3 h. 
The levels of phosphorylated PKC-θ and total PKC-θ were determined by immunoblotting. B, BxPC-3 cells were treated with AH6809/
GW627368X (5 µM each) for 1 and 3 h. The levels of phosphorylated PKC-θ and total PKC-θ were determined by immunoblot analysis. 
C, A pseudosubstrate of PKC-θ (10 µM, Millipore) was added with AH6809/GW627368X (5 µM each) pretreatment and the cell growth 
and phosphorylation of MEK and ERK were determined by MTT assays and immunoblotting, respectively. The A550 values for untreated 
cells were assigned as 100% and the relative percentages for treated cells are shown. The relative levels of phospho-MEK and -ERK were 
calculated using ImageJ software. PS, pseudosubstrate; Columns, mean percentages (n = 6); bars, SD.
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The relative expression levels of phospho-PKC-θ were 
significantly elevated in tumors treated with AH6809/
GW627368X. The phospho-MEK levels decreased only 
marginally but a significant decrease in the phospho-ERK 
levels was observed (Fig 6C).
Concomitant expression of IGF-1R, EP2/
EP4, MAP4K3, and PKC-θ in specimens from 
pancreatic cancer patients
To assess the physiological relevance of our in vivo 
observations, we examined the expression patterns of IGF-
1R, EP2/EP4, MAP4K3, and PKC-θ in surgical specimens 
from pancreatic cancers based on immunohistochemical 
analyses. The pancreatic cancer specimens comprised 
two Grade I, one Grade II, 10 Grade III, and 10 Grade IV 
cancers. All of the specimens expressed EP2 and EP4, and 
47.8%, 52.2%, and 60.9% of the specimens were positive 
for IGF-1R, MAP4K3, and PKC-θ, respectively (data not 
shown). Concomitant expression of all of these proteins 
was observed in 17.4% of the cancer specimens (data not 
shown). The representative case of quadruple positive is 
shown in Fig 7.
Figure 4: PKC-θ knockdown offsets the effects of the antagonism of EP2/EP4 signaling by compensatory induction 
of PKC-α. A, Knockdown using PKC-θ siRNA was performed in BxPC-3 cells and confirmed by immunoblotting. Cells transfected 
with negative control siRNA and PKC-θ siRNA were stimulated with IGF-1 for 48 h or 20 min in the absence or presence of AH6809/
GW627368X pretreatment for 3 h, and then tested by growth stimulation assays and immunoblotting. The A550 values for untreated cells 
were assigned as 100% and the relative percentages for treated cells are shown. The relative levels of phospho-MEK and -ERK were 
calculated using ImageJ software. Columns, mean percentages (n = 6); bars, SD. B, The expression levels of PKC-α, PKC-β, PKC-γ, 
PKC-δ, PKC-ε, PKC-η, PKC-θ, PKC-ζ, PKC-ι, and β-actin mRNA were determined in BxPC-3 cells transfected with negative control 
siRNA and PKC-θ siRNA.
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Figure 5: MAP4K3 plays a key role in the activation of PKC-θ by EP2/EP4 antagonism. A, BxPC-3 cells were stimulated 
with IGF-1 (20 ng/mL) for 20 min in the absence or presence of AH6809/GW627368X (5 µM each) pretreatment for 3 h. The levels 
of phosphorylated PDK1, total PDK1, phosphorylated AMPKα, total AMPKα, and MAP4K3 were determined by immunoblotting. B, 
Knockdown was performed with specific siRNAs for MAP4K3 and PDK1 in BxPC-3 cells and confirmed by immunoblotting. C, Cells 
transfected with negative control siRNA, MAP4K3 siRNA (#0140), and PDK1 siRNA (#4485) were stimulated with IGF-1 (20 ng/mL) 
for 48 h in the absence or presence of AH6809/GW627368X (5 µM each) pretreatment for 3 h. Cell growth was measured by the MTT 
assay. The A550 values for untreated cells were assigned as 100% and the relative percentages for treated cells are shown. Columns, mean 
percentages (n = 6); bars, SD. D, Cells transfected with negative control siRNA, MAP4K3 siRNA (#0140), and PDK1 siRNA (#4485) were 
stimulated with IGF-1 (20 ng/mL) for 20 min in the absence or presence of AH6809/GW627368X (5 µM each) pretreatment for 3 h. The 
levels of phosphorylated PKC-θ, total PKC-θ, phosphorylated MEK, total MEK, phosphorylated ERK, and total ERK were determined by 
immunoblotting. The relative levels of phospho-PKC-θ, -MEK and -ERK were calculated using ImageJ software.
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Figure 6: Effect of EP2/EP4 antagonism on IGF-1-expressing pancreatic tumor growth in vivo. A, The body weights 
of mice were measured (left) at 0, 7, 14, 21, 28, and 35 days after injection. Bars, SD. Macroscopic tumors from control and AH6809/
GW627368X-treated mice (center). The average tumor weights were calculated for each group (right). Columns, mean; bars, SD. B, H&E 
staining and immunohistochemical staining of IGF-1 and Ki-67 in tumor lesions. The percentage of Ki-67-positive cells was calculated. 
Columns, mean; bars, SD. C, Proteins from tumors were subjected to immunoblotting and the relative levels of phospho-PKC-θ, -MEK, 
and -ERK were calculated using ImageJ software. Asterisk, targeted band; Columns, mean; bars, SD.
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DISCUSSION
Crosstalk between signaling pathways contributes 
to tumor progression, metastasis, and the acquisition 
of resistance to anti-cancer drugs. Thus, an improved 
understanding of these interactions may facilitate the 
identification of novel targets and the development of 
effective anti-cancer strategies. Although many patterns 
of signaling crosstalk have been demonstrated, only few 
signaling pathways have been associated with EPs. In 
the present study, we characterized a novel interaction 
between EP2/EP4 and IGF-1R signaling pathways mainly 
in pancreatic cancer cells.
Initially, we examined the mRNA expression 
patterns of COX, EP receptors, and several growth factor 
receptors in four pancreatic cancer cell lines. Among 
these cell lines, BxPC-3 cells exhibited the most marked 
COX- and EP4-dependent constitutive positive feedback 
loop and they secreted PGE2 into CM; thus, they were 
used in further experiments. Because IGF-1R, IGF-2R, 
and NRDc were expressed in BxPC-3 cells, we performed 
growth stimulation assays following treatment with IGF-
1, IGF-2, and HB-EGF. Pretreatment with the EP2/EP4 
antagonists AH6809/GW627368X completely blocked 
growth stimulation on treatment with IGF-1 and HB-EGF 
and partially blocked it following treatment with IGF-
2. Similar reactions were observed in IGF-1-stimulated 
MCF-7 and DU145 cells, which expressed EP2, EP4, and 
IGF-1R, respectively (Supplementary Fig 2B and Ref. 
35, 36). This result suggests that the similar interaction 
may occur not only in pancreatic cancer cells but also in 
various types of cancer cells including breast and prostate 
cancer, if both the feedback loop of COX-EP (2 and/or 
4)-PGE2 production and IGF-1R expression exhibited. 
The partial suppression of IGF-2-stimulated cell growth 
may reflect as differences in the binding affinity of 
IGF-1R, which may offset the effects of IGF-2 by IGF-
2R. In agreement with the growth stimulation assays, 
corresponding phosphorylation levels of MEK and ERK 
were confirmed. Moreover, the phosphorylation of Akt, 
which is a key molecule in the other main IGF-1-mediated 
signaling pathways, was not significantly altered under 
these conditions (data not shown). Overall, these data 
indicate the primary contribution of EP2/EP4 signaling to 
IGF-1R-mediated growth and MAPK signaling.
Kinase activation and subsequent phosphorylation 
are central components of cell signal transduction. 
The AH6809/GW627368X pretreatments blocked 
the phosphorylation and activation of MEK and 
ERK, so we performed phospho-antibody arrays that 
demonstrated the dramatic phosphorylation of PKC-θ 
Thr538, which presumably leads to increased kinase 
activity. PKC-θ plays essential roles in the regulation of 
peripheral T cell activation, prevention of T cell anergy, 
T cell differentiation, and autoimmune pathogenesis 
[37]. PKC-θ overexpression has been demonstrated in 
gastrointestinal stromal tumors [38]; however, its main 
roles, including those in pancreatic cancer, have not been 
examined. Treatments with AH6809/GW627368X alone 
induced PKC-θ phosphorylation, indicating that EP2/EP4 
signaling may negatively regulate PKC-θ phosphorylation. 
Moreover, the direct inhibition of PKC-θ using a 
pseudosubstrate caused further decrease in cell viability, 
Figure 7: H&E and immunohistochemical staining for IGF-1R, EP2, EP4, MAP4K3, and PKC-θ in the representative 
case of quadruple positive. The tumor specimen co-expressed all of the proteins.
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as well as suppression of the phosphorylation of MEK 
and ERK. Thus, phosphorylated PKC-θ may be associated 
with cell survival, maintenance of cell viability, and cell 
proliferation. Inhibition of the basal activity of PKC-θ 
also suppressed IGF-1-mediated growth stimulation (data 
not shown). Some studies suggest that IGF-1/IGF-1R 
signaling directly upregulates the anti-apoptotic protein 
bcl-2 and stabilizes the integrin α5β1, which is associated 
with the MAPK pathway and cell growth, where its 
activation and/or function was influenced by PKC activity 
[39-42]. Based on these reports, we suggest that other 
cellular events may occur independently of EP2/EP4 
signaling-mediated crosstalk in IGF-1-treated cells. Under 
these conditions, the impact of PKC-θ activity on cell 
survival (anti-apoptotic) and growth may increase. Thus, 
a treatment with AH6809/GW627368X activates PKC-θ, 
and the effect of the PKC-θ pseudosubstrate may further 
decrease the cell viability. PKC-θ knockdown impaired 
the effects of AH6809/GW627368X pretreatment and 
induced the expression of PKC-α mRNA, suggesting 
that the compensatory induction of PKC-α, following the 
knockdown of PKC-θ, protected against the effects of 
AH6809/GW627368X. This result suggests that an RNA 
interference-based therapy may be limited to molecular 
targets with compensatory isoforms, and thus specific 
inhibitors or pseudosubstrates with appropriate toxicity, 
in vivo stability, and pharmaceutical availability may be 
required. The phospho-antibody arrays also indicated that 
the phosphorylation of IRS-1, which is closely related to 
the activation of the phosphoinositide-3 kinase (PI3K)/Akt 
signaling pathway, was induced by AH6809/GW627368X 
pretreatment in IGF-1 treated cells. The PI3K/Akt pathway 
is a key molecule in another major IGF-1-mediated 
signaling pathway; however, we found no changes in of 
Akt phosphorylation, as described above. Bouzakri et al. 
reported that the phosphorylation of IRS-1 Ser636/639 is 
associated with the reduced phosphorylation of IRS-1 on 
tyrosine and subsequent reduction in PI3K/Akt activation 
[43]. This may explain why Akt phosphorylation remained 
unchanged under our experimental conditions.
PKC-θ was reported to be phosphorylated 
by the kinases PDK1, AMPK, and MAP4K3 [33]. 
Immunoblotting showed that there were no increases 
in PDK1 and AMPK phosphorylation or changes in 
MAP4K3 level with AH6809/GW627368X pretreatment. 
However, MAP4K3 knockdown prevented the suppression 
of growth stimulation, phosphorylation of PKC-θ, and 
downregulation of phospho-MEK and -ERK by AH6809/
GW627368X pretreatment, whereas the negative control 
siRNA and PDK-1 knockdown did not. These data indicate 
that MAP4K3 is activated and that it phosphorylates 
PKC-θ in AH6809/GW627368X-pretreated IGF-1 treated 
cells. MAP4K3 (also known as GLK) activates JNK family 
proteins in response to cellular stress and is expressed 
in several tissues including pancreas [44]. MAP4K3 
activity is also regulated by amino acid sufficiency and 
the relevant phosphorylation sites have been identified 
[45]. However, further investigations using currently 
unavailable anti-phospho-MAP4K3 antibodies or specific 
inhibitors of MAP4K3 are required to determine whether 
AH6809/GW627368X pretreatment directly activates 
MAP4K3. AH6809/GW627368X pretreatment may also 
produce cellular stress, including alterations in the amino 
acid content, so further studies of the relationship between 
EP2/EP4 signaling and cellular stress-induced signal 
transduction are required to fully characterize the role of 
MAP4K3 in the present conditions.
To confirm the interactions between EP2/EP4 and 
IGF-1R signaling in vivo, we established an orthotopic 
xenograft model where IGF-1R signaling stimulated 
tumor growth. Initially, we established a stable transfectant 
cell line expressing hmIGF-1, which grew more rapidly 
than the vector-control cells and responded to AH6809/
GW627368X treatment. The apparent induction of tumor 
growth was observed after the injection of this transfectant 
into the pancreas of nude mice. Using this transfectant, we 
examined the effects of AH6809/GW627368X treatment, 
which suppressed tumor growth and decreased the number 
of Ki-67-positive cells. Moreover, immunohistochemical 
analyses revealed that IGF-1 expression was preserved 
during the experimental period, thereby indicating their 
similarity to the in vitro conditions that we utilized. 
Immunoblotting of tumor lesions also detected significant 
alterations in the phosphorylation status of PKC-θ and 
ERK, as shown in vitro. PGE2 also exerts various effects 
on the immune system. With respect to tumor immunity, 
PGE2 acts as an enhancer of tumor-suppressive regulatory 
T cells and macrophages (M2 macrophages). PGE2 also 
suppresses the function of NK cells and cytotoxic T 
lymphocytes, as well as contributes to the breakdown of 
the Th1/Th2 balance [46]. Thus, the mice in this model 
were athymic and treatment with AH6809/GW627368X 
could enhance the T cell-associated host tumor-immunity 
as well as obtaining additive and/or synergistic effects 
in general conditions, in addition to the effect of the 
EP antagonists itself. There was a strong agreement 
between the results of in vitro and in vivo experiments, 
so we performed clinico-pathological analyses of surgical 
specimens from pancreatic cancer patients. According to 
these analyses, 17.4% of the cases were quadruple-positive 
for IGF-1R, EP2/EP4, MAP4K3, and PKC-θ, indicating 
that crosstalk may occur between these signaling 
pathways in human pancreatic cancers. Report from 
Koshiba et al., which demonstrated that COX-2-positive 
rate in pancreatic cancer is very high [47], also assists 
the probability of this crosstalk. Although the quadruple-
positive rate of 17.4% is not very high, this result suggests 
that our in vitro and in vivo findings may be reflected 
in the clinical stages. In addition, these molecules were 
detected by immunohistochemistry using formaldehyde-
fixed paraffin blocks. Because the states of the paraffin 
blocks and the surgical specimens were highly variable, 
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it is possible that this may have caused the positive rate 
for each parameter to appear relatively low. Therefore, 
the positive rate may increase if another detection method 
is applied (e.g., immunoblotting or RT-PCR using fresh 
samples). These results also suggest that the specific 
inhibition by PKC-θ may effectively suppress cancer cell 
viability via changes in EP2/EP4 signaling in cases that 
are quadruple-positive for IGF-1R, EP2 or EP4, MAP4K3, 
and PKC-θ. Thus, specific small-molecule inhibitors of 
PKC-θ could be developed for combination therapy with 
EP2/EP4 antagonists to exploit this novel molecular target 
for cancers that co-express IGF-1R, EP2 or EP4, and 
PKC-θ. Combinations of anti-IGF-1R antibodies or small 
molecule inhibitors of IGF-1R with gemcitabine, which 
are used widely to treat pancreatic cancer, have additive 
or synergistic effects on growth and survival [48, 49]. 
However, the presence of the EP2/EP4-MAP4K3-PKC-θ 
axis and the precise effects of gemcitabine on this remain 
unresolved.
Other unresolved mechanisms include: (i) the 
effects of EP2/EP4 signaling on HB-EGF-mediated 
cellular signaling; (ii) the involvement of other phospho-
proteins identified in our phospho-antibody arrays; (iii) the 
relationships between EP2/EP4 antagonism and MAP4K3 
activation; and (iv) the presence of these molecules in 
other types of cancer. Although the activities of these 
phospho-proteins have been reported in previous studies 
[50-52], our data indicate that multiple uncharacterized 
mechanisms require further study. Overall, our results 
demonstrate the crosstalk between EP2/EP4 and IGF-
1R signaling mainly in pancreatic cancer cells that 
produce and secrete PGE2. The production of PGE2 is 
reportedly upregulated in numerous cancer types and the 
circulating IGF-1 levels are relatively stable. Therefore, 
these molecular interactions may occur in the presence 
of anti-inflammatory drugs or EP2/EP4 antagonists. In 
these cases, PKC-θ may be a potent therapeutic target for 
decreasing the cell growth and viability in tumor lesions.
MATERIALS AND METHODS
Cells, animals, and reagents
Human pancreatic cancer cell lines MiaPaCa-2, 
BxPC-3, PANC-1, and Capan-1 were purchased from 
the European Collection of Cell Cultures (Salisbury, 
UK). Cells were maintained in DMEM (MiaPaCa-2) 
and RPMI1640 (BxPC-3, PANC-1 and Capan-1) 
supplemented with 10% FBS, 100 unit/mL penicillin 
G and 0.1 mg/mL streptomycin sulfate. Five-week-old 
male nude mice were purchased from Charles River 
Japan (Yokohama, Japan), which were housed in specific 
pathogen-free conditions. The experimental protocols 
were performed in accordance with the Care and Use 
of Laboratory Animals of the University of Tokushima 
School of Medicine and were approved by the Animal 
Care and Use Committee. Recombinant human IGF-
1 was purchased from PeproTech (Rocky Hill, NJ) and 
human HB-EGF and IGF-2 were purchased from R&D 
systems (Minneapolis, MN). The EP2-selective antagonist 
AH6809 and EP4-selective antagonist GW627368X were 
purchased from Cayman Chemical (Ann Arbor, MI). The 
pseudo-substrate of PKC-θ was purchased from Merck 
Millipore (Billerica, MA).
Expression of mRNAs and assessment of PGE2 
secretion using enzyme immunoassays
Total RNAs samples were isolated from MiaPaCa-2, 
BxPC-3, PANC-1, and Capan-1 cells using RNeasy Mini 
kits (QIAGEN, Valencia, CA). Aliquots (1 µg) were then 
subjected to semi-quantitative RT-PCR as previously 
described [53], and COX-1, COX-2, EP1, EP2, EP3, EP4, 
IR, IGF-1R, IGF-2R, EGFR, ErbB4, and NRDc were 
determined using β-actin mRNA as an internal control 
with the primer sequences listed in Supplementary Table 
1. The PGE2 concentrations were determined in CM using 
a PGE2 Express EIA kit (Cayman Chemical). 
Growth stimulation assay 
Cells (5 × 103 cells/well or 3 × 105 cells/well) 
were plated on 96-well microplates or six-well plates, 
preincubated overnight at 37°C, and then starved for 24 h 
in 100 µL or 1.5 mL of serum-free medium. Subsequently, 
equal volumes of serum-free medium containing HB-EGF, 
IGF-1, and IGF-2 (50, 20, and 50 ng/mL, respectively) 
were added, and the cells were incubated for 48 h or 
20 min at 37°C. Pretreatments with 5 µM AH6809/
GW627368X were performed for 3 h prior to the 
growth factor treatments. After stimulation, the viable 
cells were counted by the MTT method or subjected 
to immunoblotting. The immunoblotting procedure is 
described below.
Immunoblotting
Untreated, treated, knockdown cells, and orthotopic 
tumor specimens were lysed and their protein levels 
were determined by immunoblotting, as previously 
described [53]. The antibodies used in this study are 
listed in Supplementary Table 2. Signals were detected 
using an Immobilon Western horseradish peroxidase 
substrate (Merck Millipore). Signals from tumor samples 




IGF-1R signaling was assessed in IGF-1-stimulated 
and AH6809/GW627368X-pretreated IGF-1-stimulated 
BxPC-3 cells (5 × 106) using a Phospho Antibody 
Array contract service (FullMoon BioSystems Inc; 
Filgen, Nagoya, Japan). The protein phosphorylation 
levels were normalized against the corresponding total 
protein concentrations and the fold changes in AH6809/
GW627368X-pretreated IGF-1-stimulated BxPC-3 cells 
were expressed relative to those in IGF-1-stimulated 
BxPC-3 cells. The concentrations of IGF-1, AH6809, and 
GW627368X were the same as those used in the growth 
stimulation assays. Pretreatments and treatments were 
performed for 3 h and 20 min, respectively.
RNA interference
BxPC-3 cells (3 × 105 cells/well) were seeded onto 
six-well plates and preincubated overnight at 37°C. The 
following day, the cells were transfected with negative 
universal control siRNA (Life Technologies, Carlsbad, 
CA), PKC-θ siRNA (ID SASI_Hs01_00239143; Sigma), 
MAP4K3 siRNA (ID SASI_Hs02_00335960 and SASI_
Hs01_00040140; Sigma) and PDK1 siRNA (ID SASI_
Hs01_00094378 and SASI_Hs01_00044485; Sigma) using 
lipofectamine RNAiMAX (Life Technologies), according 
to the manufacturer’s protocol. After transfection, we 
analyzed the effects of AH6809/GW627368X on IGF-
1-stimulated cell growth and the activations of PKC-θ, 
MEK, and ERK with a growth stimulation assay and 
immunoblotting using the conditions and procedures 
described above. Total RNA samples were isolated from 
negative control siRNA- and PKC-θ siRNA-transfected 
cells using RNeasy Mini kits, and aliquots (1 µg/sample) 
were then subjected to semi-quantitative RT-PCR. The 
conditions and procedures are previously described [53]. 
The levels of PKC-α, PKC-β, PKC-γ, PKC-δ, PKC-ε, 
PKC-η, PKC-θ, PKC-ζ, and PKC-ι mRNA were quantified 
using the primer sequences listed in Supplementary Table 
1. β-actin mRNA was used as an internal standard.
Orthotopic xenograft model in nude mice
Mice were anesthetized with ketamine and xylazine 
(1.8 and 0.8 mg/mouse, respectively) and surgery was 
performed. Briefly, a small left flank incision was made 
and the pancreas was exteriorized. Intrapancreatic 
injections of BxPC-hmIGF1 cells (1.2 × 106 cells/
mouse) were then performed using a 30-gauge syringe. 
To avoid intraperitoneal leakage of the cell suspensions, 
the injected region was pressed with a sterilized cotton 
swab for 10 s. Both layers of the abdominal wounds were 
closed with wound clips. The mice were then treated daily 
with intraperitoneal saline (n = 10) or 4 mg/kg AH6809/
GW627368X (n = 10) from the next day. After 35 days, 
the mice were euthanized and their tumor lesions were 
collected and weighed. Parts of the tumor specimens 
were retained for immunoblotting and the remaining 
tumor tissues were then fixed in 10% phosphate-buffered 
formaldehyde.
Histological analyses
Formaldehyde-fixed tissues were embedded in 
paraffin and sectioned at 4 µm. All of the sections were 
subjected to H&E staining and immunohistochemical 
staining for IGF-1 and Ki-67. Quantitative analyses were 
performed by microscopically counting the numbers 
of Ki-67-positive cells per field. The antibodies used 
in this study are listed in Supplementary Table 2. The 
sections were blocked with 1% hydrogen peroxide in 
50% methanol before probing with primary antibodies. 
The antigens on the paraffin sections were then retrieved 
by autoclaving in 0.01 M citrate buffer (pH 6.0) for 10 
min and visualized using a ChemMate Envision kit with 
a horseradish peroxidase/3,3’-diaminobenzidine kit. All 
sections were counterstained with Mayer’s hematoxylin 
(Muto Pure Chemicals, Tokyo, Japan).
Clinico-pathological analysis
Formaldehyde-fixed paraffin blocks from 23 
surgically resected pancreatic cancers were obtained 
from Tokushima University Hospital (2005-2011). 
Serial sections (4 µm thickness) were cut and 
immunohistochemical staining was performed for 
IGF1R, EP2, EP4, MAP4K3, and PKC-θ. Pathologists 
differentiated the slides as positive or negative for antigens 
in a double-blinded test. The antibodies used in this study 
are listed in Supplementary Table 2. Antigen retrieval, 
visualization, and counterstaining were performed as 
described above.
Statistical analysis
The body weights, tumor weights, Ki-67-labeling 
indices, and immunoblotting data were compared using 
two-tailed Mann-Whitney U tests. All other comparisons 
were performed using two-tailed Student’s t-tests and the 
differences were considered statistically significant when 
P < 0.05.
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